awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36682843-1037B2B9-8F82-424D-8420-4F73D756579D
Q36682843-1037B2B9-8F82-424D-8420-4F73D756579D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36682843-1037B2B9-8F82-424D-8420-4F73D756579D
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
P2860
Q36682843-1037B2B9-8F82-424D-8420-4F73D756579D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36682843-1037B2B9-8F82-424D-8420-4F73D756579D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
551a2aa7df968032b593097c6e7287432012f5fc
P2860
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.